Abstract 329P
Background
The first patient infected with the COVID-19 virus in Algeria was reported on February 25, 2020. Radiotherapy departments are potentially exposed like others to the COVID-19 pandemic and this is a crucial issue since cancer patients cannot interrupt their treatment. The objective of this study is to describe the different epidemiological and therapeutic aspects of patients treated with palliative radiotherapy at the time of COVD-19.
Methods
It is a prospective study of the files of 28 patients treated aimed palliative at the radiotherapy department of the cancer center Tlemcen, Algeria since the new guidelines of our department to contain the spread of the pandemic from March 19 to April 30.
Results
They are 19 men and 9 women (sex ratio 2.11) with a median age of 61 years (35-87). 13 patients (46.42%) had brain metastases, six patients (21.42%) had bone metastases, two patients (7.14%) had esophagus, two patients (7.14%) had maxillofacial metastases and five (17.87%) patients had other localizations (lung, thyroid, sarcoma, multiple myeloma and glioblastoma). 30GY protocol was delivered in six (21.42%) patients, 20GY protocol was delivered in 16 (57.14%) patients and 8GY protocol was delivered in five (17.87%) patients.11 cases (84.61%) of brain metastases were treated with 20GY, five cases (83.33%) of bone metastases were treated with 8GY. No cases were infected with the virus.
Conclusions
Palliative radiotherapy plays a critical role in preventing serious morbidity in cancer patients even in the midst of the current COVID-19 pandemic. The acute phase of the pandemic has led to major changes in radiotherapy treatment strategy, including the use of hypo-fractionated regimens for palliative radiotherapy, which are preferred to reduce patients' risk of exposure to COVID-19 and to limit treatment delays. Hypo fractionation is one option that could at least partially address these issues.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Mous.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session